Abstract
Twenty patients with acute myeloid leukaemia (AML) were treated with a combination of chemotherapy which included daunorubicin, cytosine arabino-side and 6-thioguanine (DAT). The complete remission rate was 85% and was achieved, in responsive cases, after an average of 2 courses of therapy. Patients remained in hospital for an average of 37.5 days during remission-induction therapy and 3.7 days per month thereafter. The median remission period was 48 weeks and median survival was 70 weeks. A disappointing feature was the high relapse rate. This feature of the results re-affirms the need for a more effective form of remission therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Rees, J., Sandler, R., Challener, J. et al. Treatment of acute myeloid leukaemia with a triple cytotoxic regime: dat. Br J Cancer 36, 770–776 (1977). https://doi.org/10.1038/bjc.1977.260
Issue Date:
DOI: https://doi.org/10.1038/bjc.1977.260
- Springer Nature Limited
This article is cited by
-
Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside
Cancer Chemotherapy and Pharmacology (1987)
-
Uptake of adriamycin by human leukemic cells as measured by flow cytometry
Medical Oncology and Tumor Pharmacotherapy (1984)